Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1823 1
1850 1
1921 1
1922 1
1931 1
1933 1
1950 4
1951 3
1952 5
1953 3
1954 2
1955 6
1956 12
1957 11
1958 5
1959 8
1960 8
1961 1
1962 5
1963 9
1964 6
1965 1
1966 3
1967 4
1968 1
1969 3
1970 3
1972 1
1973 4
1974 2
1975 2
1976 14
1977 22
1978 3
1979 1
1980 6
1981 3
1982 3
1984 4
1985 4
1986 2
1987 6
1988 9
1989 11
1990 10
1991 15
1992 20
1993 22
1994 14
1995 14
1996 22
1997 18
1998 50
1999 57
2000 82
2001 76
2002 125
2003 137
2004 172
2005 195
2006 228
2007 233
2008 248
2009 254
2010 279
2011 321
2012 376
2013 366
2014 446
2015 587
2016 590
2017 557
2018 670
2019 736
2020 874
2021 973
2022 967
2023 921
2024 1046
2025 1174
2026 313

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,918 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: inarno
Page 1
Showing results for alex inarno
Your search for Alex Winarno retrieved no results
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
BACKGROUND: Mature progression-free survival (PFS) data from the phase III J-ALEX study showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.26-0.52; median PFS 34.1 versus 10.2 months, respectively] in advanced ALK (an …
BACKGROUND: Mature progression-free survival (PFS) data from the phase III J-ALEX study showed superiority for alectinib versus crizo …
Alex Schuppe.
[No authors listed] [No authors listed] Angew Chem Int Ed Engl. 2024 Jul 8;63(28):e202409073. doi: 10.1002/anie.202409073. Epub 2024 Jun 11. Angew Chem Int Ed Engl. 2024. PMID: 38860347
These experiences were very formative, as they gave me a preview of what the start of my own independent career would be like Chemistry is fun because you get to envision and discover new ways to make and manipulate molecules " Find out more about Alex Schuppe in his Intr …
These experiences were very formative, as they gave me a preview of what the start of my own independent career would be like Chemistry is …
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials.
Attili I, Fuorivia V, Spitaleri G, Corvaja C, Trillo Aliaga P, Del Signore E, Asnaghi R, Carnevale Schianca A, Passaro A, de Marinis F. Attili I, et al. Cancers (Basel). 2024 Jul 4;16(13):2457. doi: 10.3390/cancers16132457. Cancers (Basel). 2024. PMID: 39001519 Free PMC article. Review.
We performed an analytic, 'non-comparative' assessment of the two phase 3 pivotal clinical trials showing superiority of alectinib (ALEX) and lorlatinib (CROWN) in comparison to crizotinib. Overall, the two studies were very similar in the study design and patient characte …
We performed an analytic, 'non-comparative' assessment of the two phase 3 pivotal clinical trials showing superiority of alectinib (ALEX …
Xeroderma pigmentosum.
Webb S. Webb S. BMJ. 2008 Feb 23;336(7641):444-6. doi: 10.1136/bmj.39485.698356.AD. BMJ. 2008. PMID: 18292171 Free PMC article. Review.
Alex Webb was 4 years old when he was diagnosed with xeroderma pigmentosum nine years ago. ...
Alex Webb was 4 years old when he was diagnosed with xeroderma pigmentosum nine years ago. ...
Alex Kacelnik.
Kacelnik A. Kacelnik A. Curr Biol. 2010 Aug 24;20(16):R662-3. doi: 10.1016/j.cub.2010.06.054. Curr Biol. 2010. PMID: 21174389 Free article. No abstract available.
Altitude illness.
Alex J. Alex J. Curr Sports Med Rep. 2015 Mar-Apr;14(2):82-3. doi: 10.1249/JSR.0000000000000127. Curr Sports Med Rep. 2015. PMID: 25756999 Review. No abstract available.
Alex Sinclair.
[No authors listed] [No authors listed] Lancet Neurol. 2015 Dec 11:S1474-4422(15)00384-1. doi: 10.1016/S1474-4422(15)00384-1. Online ahead of print. Lancet Neurol. 2015. PMID: 26700868 No abstract available.
11,918 results
You have reached the last available page of results. Please see the User Guide for more information.